Health-tech company Evinova and biopharmaceutical company Harbour BioMed (HKEX:02142) on Friday announced a strategic collaboration to apply artificial intelligence (AI) and digital technologies to drug discovery and development.

The partnership aims to enhance the efficiency of biologics R&D and establish an open ecosystem for AI-driven innovation.

Evinova China will contribute its expertise in AI-powered clinical development solutions and digital strategy consulting, drawing on global pharmaceutical insights to accelerate health outcomes. Harbour BioMed will leverage its proprietary Harbour Mice technology platform and experience in immunology and oncology.

The two companies intend to combine Evinova's advanced AI platforms with Harbour BioMed's therapeutic capabilities to improve clinical study efficiency and speed the delivery of novel antibody therapies to patients worldwide. The collaboration underscores both firms' shared ambition to advance China-originated breakthrough assets on a global scale.